摘要
目的 分析帕罗西汀联合喹硫平治疗双相情感障碍抑郁发作临床疗效。方法 选择2021年2月—2022年2月哈尔滨市第一专科医院收治双相情感障碍抑郁发作患者86例,按随机数字表分为两组,对照组43例使用帕罗西汀治疗,研究组43例使用帕罗西汀联合喹硫平治疗,比较两组临床疗效及不良反应。结果研究组患者治疗后1周(20.75±4.11)分、2周(14.22±3.17)分、4周(10.22±2.51)分、6周(6.45±1.44)分的抑郁评分显著低于对照组,对比差异有统计学意义(P <0.05);研究组恶心呕吐、嗜睡、失眠及坐立不安等不良反应发生率明显低于对照组,对比差异有统计学意义(P <0.05);研究组患者治疗后社会功能(85.32±4.40)分、躯体功能(86.25±1.30)分、心理功能(87.27±2.62)分、物质生活(86.26±2.30)分均高于对照组,差异有统计学意义(P <0.05)。结论 帕罗西汀联合喹硫平用于双相情感障碍抑郁发作患者治疗中,可减轻患者抑郁度,减少不良反应出现率,能进一步提升其生活质量,值得临床推广使用。
Objective To analyze the clinical efficacy of paroxetine combined with quetiapine in the treatment of depressive episode of bipolar disorder.Methods A total of 86 patients with bipolar disorder with depressive episode admitted to The First Psychiatric Hospital of Harbin from February 2021 to February 2022 were selected and divided into two groups according to the random number table.The control group(n=43) was treated with paroxetine,and the study group(n=43)was treated with paroxetine combined with quetiapine.The clinical efficacy and adverse reactions of the two groups were compared.Results The depression scores of the study group at 1 week(20.75±4.11)points,2 weeks(14.22±3.17) points,4 weeks(10.22±2.51) points and 6 weeks(6.45±1.44) points after treatment were significantly lower than those of the control group,and the differences were statistically significant(P < 0.05).The incidence of adverse reactions such as nausea and vomiting,drowsiness,insomnia and restlessness in the study group was significantly lower than that in the control group,and the difference was statistically significant(P < 0.05).After treatment,the scores of social function(85.32±4.40) points,physical function(86.25±1.30) points,psychological function(87.27±2.62) points and material life(86.26±2.30) points in the study group were higher than those in the control group,and the differences were statistically significant(P < 0.05).Conclusion Roxetine combined with quetiapine in the treatment of patients with depressive episodes of bipolar affective disorder can reduce the degree of depression,reduce the incidence of adverse reactions,and improve the quality of their daily life.It is worthy of clinical use.
作者
薛斌
许冰岚
杜熔淦
XUE Bin;XU Binglan;DU Ronggan(Department of Rehabilitation,The First Psychiatric Hospital of Harbin,Harbin Heilongjiang 150000,China)
出处
《中国卫生标准管理》
2022年第20期124-127,共4页
China Health Standard Management
